ClinicalTrials.Veeva
Menu

Find clinical trials for Non-Small-Cell Lung Cancer in Toronto, ON

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Colorectal Cancer
Cancer
Squamous Cell Carcinoma of Head and Neck
Neoplasm Metastasis
Melanoma

Non-Small-Cell Lung Cancer trials near Toronto, ON, CAN:

Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)

in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with o...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Docetaxel
Drug: DS-1062a

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Toronto, Ontario, Canada and 210 other locations

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Sunvozertinib

Phase 1, Phase 2

Dizal Pharma

Toronto, Canada and 124 other locations

Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients Undergoing Chemoradiation (P4-PACIFIC)

Currently, the standard of care treatment for newly diagnosed, inoperable stage III non-small cell lung cancer...

Enrolling
Radiation Induced Lung Injury (RILI)
Non-Small Cell Lung Cancer
Other: Placebo
Other: α-Tocopherol

Phase 2

University Health Network, Toronto
University Health Network, Toronto

Toronto, Ontario, Canada

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) (LIBRA)

This is a Phase II, multi-center, open-label platform study evaluating novel combination treatment options in participants with locally advanced or m...

Enrolling
Non-Small Cell Lung Cancer
Drug: Dato-DXd
Drug: Ramucirumab

Phase 2

AstraZeneca
AstraZeneca

Toronto, Ontario, Canada and 82 other locations

A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer (REACH-EGFR)

This first-in-human, Phase 1/2, multicenter, open-label, non-randomized study evaluates the safety, tolerability, pharmacokinetics, pharmaco-...

Enrolling
EGFR-Mutant Non-Small Cell Lung Cancer
Drug: VRN110755

Phase 1, Phase 2

Voronoi, Inc

Toronto, Ontario, Canada and 28 other locations

An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decid ...

Enrolling
Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
Drug: SMS001

Phase 2

ToLymph Inc.

Toronto, Ontario, Canada and 1 other location

Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection (SUPER)

The SUPER trial is a prospective Phase II trial. It is designed for patients with stage 2 or 3 non-small cell lung...

Enrolling
Non-small Cell Lung Cancer (NSCLC)
Lung Cancer Patients
Radiation: Non-ablative oligofractionated radiation (NORT)
Drug: Durvalumab

Phase 2

Marc de Perrot

Toronto, Canada

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the-...

Enrolling
Non-small Cell Lung Cancer
Drug: Nab-paclitaxel
Drug: Pembrolizumab

Phase 3

AstraZeneca
AstraZeneca

Hamilton, Ontario, Canada and 324 other locations

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells...

Enrolling
Non-Squamous Non-Small Cell Lung Cancer
Drug: Standard of Care
Drug: Telisotuzumab Adizutecan

Phase 2, Phase 3

AbbVie
AbbVie

Toronto, Ontario, Canada and 52 other locations

Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Telisotuzumab vedotin

Phase 2

AbbVie
AbbVie

Toronto, Ontario, Canada and 254 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems